poisar

Stock

Faeth Therapeutics, Inc. FTH

$30.30+6.13%

Overview

FTH market data

Price History

FTH price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$16.72
Diluted earnings per share over the trailing twelve months.
Beta
2.09
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$13.43 – $37.90
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $738.3M.

Company News

10 captured
HC Wainwright & Co. Reiterates Buy on Faeth Therapeutics, Maintains $60 Price TargetBenzinga · Aug 11, 2026, 12:17 PM
Faeth Therapeutics To Present Translational Data And Pharmacokinetic/Pharmacodynamic Analysis For PIKTOR, Oral Combination Of Serabelisib And Sapanisertib, At 2026 Summit For STOP CancerBenzinga · Aug 7, 2026, 11:35 AM
Faeth Therapeutics shares are trading lower after the company reported a wider net loss for the second quarter driven by a sharp increase in expenses.Benzinga · Aug 4, 2026, 2:22 PM
8-K filing — Faeth Therapeutics, Inc. (FTH)SEC EDGAR · Aug 4, 2026, 11:40 AM
Faeth Therapeutics Q2 EPS $(2.84) Beats $(3.29) EstimateBenzinga · Aug 4, 2026, 11:34 AM
This Faeth Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For FridayBenzinga · Jul 31, 2026, 1:11 PM
This Plexus Analyst Turns Bullish; Here Are Top 4 Upgrades For FridayBenzinga · Jul 31, 2026, 11:47 AM
Raymond James Initiates Coverage On Faeth Therapeutics with Outperform Rating, Announces Price Target of $56Benzinga · Jul 31, 2026, 10:14 AM
This Crowdstrike Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For TuesdayBenzinga · Jul 28, 2026, 1:02 PM
Oppenheimer Initiates Coverage On Faeth Therapeutics with Outperform Rating, Announces Price Target of $60Benzinga · Jul 28, 2026, 9:26 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock